XOMA announces license agreement with Novo Nordisk XOMA (XOMA) announced it has exclusively licensed the global development and commercialization rights to its XMetA program of allosteric monoclonal antibodies that up-regulate the insulin receptor to Novo Nordisk A/S (NVO). Under the terms of the agreement, XOMA retains commercialization rights for rare disease indications. Novo Nordisk has an option to add these additional rights in rare diseases to its license. XOMA will receive $5.0M in the form of an upfront payment, and the agreement includes up to $290.0M in additional potential development, regulatory and commercial milestones. In addition, XOMA is eligible to receive tiered royalties on product sales.